Vaccine Patent
May 26 2010 - 2:00AM
RNS Non-Regulatory
TIDMLPX
Lipoxen PLC
26 May 2010
?
+---------------------------------+---------------------------------+
| FOR IMMEDIATE RELEASE | 26 May 2010 |
| RNS Reach | |
+---------------------------------+---------------------------------+
Lipoxen plc
('Lipoxen' or 'the Company')
Expansion of DNA Vaccine Patent Allowed in US
Lipoxen plc (AIM: LPX), a bio-pharmaceutical company specialising in the
development of high-value differentiated biologicals, vaccines and siRNA
delivery, announces today that an expansion of its DNA Vaccine Patent ("Patent")
has been allowed in the US for its ImuXen liposomal gene technology.
The ImuXen technology allows the liposomal entrapment of vaccine materials,
resulting in enhanced immune responses which potentially could lead to single
dose immunity being achieved while reducing the side effects associated with
traditional vaccines. The new Patent protects the use of a range of additional
cationic lipids that can form the building molecules of Lipoxen's ImuXen
liposomes.
This Patent expansion strengthens and broadens Lipoxen's existing ImuXen
patents which protect the co-delivery DNA and antigen and delivery of antigen
alone.
Commenting on these results, Scott Maguire, CEO said: "This Patent extension is
important as it further protects the patent position of our gene vaccine
technology. Such added protection will provide value to commercial partners
seeking long term exclusivity in the vaccine market."
For further information, please contact:
Enquiries
+------------------------------------------+--------------------+
| Lipoxen plc | +44 (0)20 7389 |
| | 5015 |
+------------------------------------------+--------------------+
| M. Scott Maguire, Chief Executive | |
| Officer | |
+------------------------------------------+--------------------+
| | |
+------------------------------------------+--------------------+
| Singer Capital Markets (nominated | +44 (0)20 3205 |
| adviser) | 7500 |
+------------------------------------------+--------------------+
| Jeff Keating / Claes Spång | |
+------------------------------------------+--------------------+
| | |
+------------------------------------------+--------------------+
| Buchanan Communications | +44 (0)20 7466 |
| | 5000 |
+------------------------------------------+--------------------+
| Lisa Baderoon, Catherine Breen | |
+------------------------------------------+--------------------+
About Lipoxen
Lipoxen plc is a biopharmaceutical company focused on the development of new and
improved biologic drugs and vaccines. Lipoxen has three proprietary patented
technology platforms:
1) PolyXen - for extending the efficacy and half life of biologic drugs
2) ImuXen - for creating new vaccines and improving existing vaccines
3) SiRNAblate - for the delivery of siRNA
Lipoxen's technology is designed to improve the efficacy, safety, stability,
biological half-life and immunologic characteristics of its products.
Lipoxen has multiple drug and vaccine programmes in development. Two products
are in clinical development, SuliXen, a long acting insulin and ErepoXen, a
long-acting erythropoietin (EPO). Lipoxen's preclinical pipeline includes
vaccines against HIV, influenza and malaria and an exclusive license deal with
Baxter Healthcare for Factor VIII.
The Company has a low-risk business model and out-licenses its proprietary
technologies to biopharmaceutical companies that have strong manufacturing and
marketing capabilities. Lipoxen currently has commercial agreements with some
of the world's leading biotechnology and pharmaceutical companies including
Baxter, Schering-Plough, the Serum Institute of India Limited, Genentech, and
Genzyme. Furthermore, Baxter, the Company's third largest shareholder, and
management led the GBP2.9 million fundraising that the Company announced in May
2009. This fundraising was followed up by a GBP1.2 million placing in April
2010.
Lipoxen, which was founded in 1997, trades on the AIM Market of the London Stock
Exchange under the ticker symbol LPX. More information can be found at the
Company's website: www.lipoxen.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAQELFLBEFLBBL
Lipoxen (LSE:LPX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Lipoxen (LSE:LPX)
Historical Stock Chart
From Sep 2023 to Sep 2024